Risk factors for Mycoplasma genitalium infection, including demographic data
| Logistic regression risk factor analysis for being MG positive pre-MDA and post-MDA | ||||||||||
| Pre-MDA | Post-MDA | |||||||||
| Univariate analysis | Univariate analysis | |||||||||
| Characteristic | Participants, n | With MG*, n (%) | OR | 95% CI | P value | Participants, n | With MG*, n (%) | OR | 95% CI | P value |
| Age group (years) | ||||||||||
| 15–24 | 68 | 9 (13.2) | 1.00 | 113 | 13 (11.5) | 1.00 | ||||
| 25–34 | 104 | 10 (9.6) | 0.70 | 0.27 to 1.82 | 0.461 | 114 | 11 (9.7) | 0.82 | 0.35 to 1.92 | 0.650 |
| 35–44 | 39 | 6 (15.4) | 1.19 | 0.39 to 3.64 | 0.758 | 28 | 4 (14.3) | 1.28 | 0.38 to 4.28 | 0.686 |
| 45-64† | 11 | 0 (0) | – | – | – | 0 | 0 (0) | – | – | – |
| Data unavailable | 14 | 1 | ||||||||
| Clinic | ||||||||||
| K | 94 | 11 (11.7) | 1.00 | 77 | 10 (13.0) | 1.00 | ||||
| M | 64 | 7 (10.9) | 0.93 | 0.34 to 2.53 | 0.882 | 86 | 12 (14.0) | 1.09 | 0.44 to 2.68 | 0.857 |
| R | 78 | 9 (12.0) | 1.03 | 0.40 to 2.63 | 0.953 | 92 | 6 (6.5) | 0.47 | 0.16 to 1.35 | 0.160 |
| Data unavailable | 0 | 1 | ||||||||
| Ethnicity | ||||||||||
| Melanesian | 212 | 25 (11.8) | 1.00 | 228 | 26 (11.4) | 1.00 | ||||
| Other | 14 | 2 (14.3) | 1.25 | 0.26 to 5.90 | 0.781 | 24 | 2 (8.3) | 0.71 | 0.16 to 3.18 | 0.650 |
| Data unavailable | 10 | 4 | ||||||||
| Urban/Rural | ||||||||||
| Urban | 214 | 22 (10.3) | 1.00 | 197 | 23 (11.7) | 1.00 | ||||
| Rural | 6 | 1 (16.7) | 1.75 | 0.19 to 15.63 | 0.618 | 46 | 3 (6.5) | 0.53 | 0.15 to 1.84 | 0.316 |
| Data unavailable | 16 | 13 | ||||||||
| Education (years) | ||||||||||
| 224 | 25 (10.7) | 1.09 | 0.99 to 1.19 | 0.082 | 255 | 28 (11.0) | 0.94 | 0.86 to 1.03 | 0.196 | |
| Data unavailable | 12 | 1 | ||||||||
| Currently married | ||||||||||
| No | 37 | 7 (18.9) | 1.00 | 51 | 6 (11.8) | 1.00 | ||||
| Yes | 192 | 19 (9.9) | 0.47 | 0.18 to 1.22 | 0.120 | 198 | 21 (10.6) | 0.89 | 0.34 to 2.33 | 0.813 |
| Data unavailable | 7 | 7 | ||||||||
| Living with partner | ||||||||||
| No | 40 | 8 (20.0) | 1.00 | 29 | 4 (13.8) | 1.00 | ||||
| Yes | 184 | 17 (9.2) | 0.41 | 0.16 to 1.02 | 0.056 | 217 | 23 (10.6) | 0.74 | 0.24 to 2.32 | 0.606 |
| Data unavailable | 12 | 10 | ||||||||
| STI in last 12 months | ||||||||||
| No | 224 | 25 (11.2) | 1.00 | 229 | 23 (10.0) | 1.00 | ||||
| Yes | 8 | 2 (25.0) | 2.65 | 0.51 to 13.9 | 0.247 | 22 | 4 (18.2) | 1.99 | 0.62 to 6.39 | 0.247 |
| Data unavailable | 4 | 5 | ||||||||
| Symptoms | ||||||||||
| No | 188 | 23 (12.2) | 1.00 | 222 | 26 (11.7) | 1.00 | ||||
| Yes | 37 | 3 (8.1) | 0.63 | 0.18 to 2.23 | 0.476 | 22 | 1 (4.5) | 0.36 | 0.05 to 2.78 | 0.327 |
| Data unavailable | 11 | 12 | ||||||||
| Gonorrhoea positive‡ | ||||||||||
| No | 228 | 25 (11.0) | 1.00 | 240 | 28 (11.7) | 1.00 | ||||
| Yes | 5 | 2 (40.0) | 5.41 | 0.86 to 33.98 | 0.072 | 15 | 0 (0) | – | – | – |
| Data unavailable | 3 | 1 | ||||||||
| TV positive§ | ||||||||||
| Negative | 146 | 14 (9.6) | 1.00 | 135 | 16 (11.9) | 1.00 | ||||
| Positive | 87 | 13 (14.9) | 1.66 | 0.74 to 3.71 | 0.220 | 120 | 12 (10.0) | 0.83 | 0.37 to 1.83 | 0.637 |
| Data unavailable | 3 | 1 | ||||||||
| Received MDA | ||||||||||
| No | N/A | N/A | N/A | N/A | N/A | 125 | 22 (17.6) | 1.00 | ||
| Yes | N/A | N/A | N/A | N/A | N/A | 126 | 5 (4.0) | 0.19 | 0.07 to 0.53 | 0.001 |
| Data unavailable | 5 | |||||||||
Risk factor analysis for M. genitalium (MG) prevalence.
*MG positive defined by FTD Urethritis Plus Kit.
†Age group 45–64 years predicted failure perfectly.
‡Positive by BD ProbeTec and/or FTD Urethritis Plus Kit.
§Positive by FTD Urethritis Plus Kit.
MDA, mass drug administration; N/A, not applicable; TV, Trichomonas vaginalis.